Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Equity Average (2017 - 2025)

Vistagen Therapeutics' Equity Average history spans 8 years, with the latest figure at $58.6 million for Q4 2025.

  • For Q4 2025, Equity Average fell 32.65% year-over-year to $58.6 million; the TTM value through Dec 2025 reached $58.6 million, down 32.65%, while the annual FY2025 figure was $92.3 million, N/A changed from the prior year.
  • Equity Average for Q4 2025 was $58.6 million at Vistagen Therapeutics, down from $61.6 million in the prior quarter.
  • Across five years, Equity Average topped out at $118.8 million in Q1 2024 and bottomed at $21.2 million in Q3 2023.
  • The 4-year median for Equity Average is $80.3 million (2021), against an average of $77.5 million.
  • The largest annual shift saw Equity Average skyrocketed 12070.1% in 2021 before it tumbled 41.96% in 2025.
  • A 4-year view of Equity Average shows it stood at $80.3 million in 2021, then decreased by 1.06% to $79.5 million in 2023, then increased by 9.54% to $87.0 million in 2024, then crashed by 32.65% to $58.6 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Equity Average are $58.6 million (Q4 2025), $61.6 million (Q3 2025), and $63.6 million (Q2 2025).